AI in Healthcare

Healthcare AI Moves From Big Investment to Trusted Intelligence

Healthcare AI is entering a new phase, and the biggest question is no longer whether the technology can attract investment. The real test is whether organizations can turn scattered clinical data, powerful models, and rising budgets into trusted research and better daily workflows.

On November 20, 2026, nference announced a long-term collaboration with Cedars-Sinai to build a secure platform for analyzing de-identified clinical data from multiple areas of patient care. The planned foundation would draw on more than a decade of records from over 5 million patients, following their care over time.

A Federated Foundation for Clinical Research

The platform still needs to be developed, but its intended design points toward a more connected approach to medical research. Nference will architect federated software that protects patient privacy while harmonizing data created in different clinical formats. Instead of treating each record type as a separate island, the system is designed to give investigators a common basis for studying therapeutic, diagnostic, and surgical care.

That foundation would convert information generated during routine care into research-ready data. Its de-identified inputs are intended to include clinical notes, laboratory results, medications, diagnostic reports, radiology and pathology images, genomic information, electrophysiology waveforms, vital signs, and flowsheet measurements. Biospecimens collected with patient consent will also be included, and frequent data refreshes will add new information as care progresses.

Longitudinal curation will organize records as patient care unfolds, with physician adjudication bringing doctor review into the preparation process. That human review matters because clinical data rarely arrives in a single clean format. It carries context across visits, tests, treatments, images, and measurements, and the planned platform aims to connect those pieces without removing the people who understand their meaning.

“Understanding health and disease requires connecting what is happening across organs, across clinical modalities, and across decades of each patient’s medical journey,” said Venky Soundararajan, founder and co-CEO of nference.

Soundararajan described the planned foundation as “whole-body spatial intelligence,” intended to triangulate disparate and unstructured modalities so difficult scientific questions become more tractable. The continually updated resource is intended to help researchers gain finer-grained insight into how diseases begin and progress, but that remains an intended benefit rather than a demonstrated research outcome.

From Research Data to AI Models and New Treatments

The planned platform is intended to support investigator-led studies, grant-funded research, education, and quality improvement. It is also designed to support collaborations with life-science industry partners and give Cedars-Sinai researchers and affiliated innovators a foundation for developing and evaluating new AI models.

Drug discovery, clinical-trial design, and future diagnostics are identified as downstream uses. Those applications depend on the studies and model evaluations the platform is meant to enable; they are not outcomes already achieved through the collaboration.

The broader healthcare AI market is already moving in that direction. Menlo Ventures’ 2026: The State of AI in Healthcare report found that healthcare AI spending reached $3.7 billion, up 2.5x in a year. The fastest growth now comes from drug discovery, clinical decision-making, and patient care.

AI is also giving cancer researchers new ways to search for potential drug targets and develop treatments. By sorting through genetic, molecular, and biological data, AI platforms can pinpoint weaknesses in cancer cells, identify promising drug candidates, and predict how different compounds may behave. Work that once required years of research and extensive laboratory screening can be narrowed down with advanced algorithms.

The global AI drug discovery market was estimated at approximately $2.3 billion in 2025. That figure, alongside the $3.7 billion in healthcare AI spending, shows how investment is spreading across both specialized research and broader clinical applications.

Definitive Healthcare also announced initial findings from an early-adopter program for its AI-powered growth intelligence platform. The program launched in August for a select group of customers, and participants have conducted more than 570 analyses since then. Health systems, life sciences organizations, and other healthcare-focused businesses have used the platform to answer complicated market questions and complete sophisticated analyses in minutes rather than weeks or months.

Investment Needs Governance, Training, and Proof

Spending alone will not determine which healthcare AI projects create lasting value. HTEC’s AI Value Realization Report 2026: Healthcare & Life Sciences found that 83% of healthcare and life sciences organizations increased AI investment in the past year, yet only 41% said their company was scaling AI or was AI-native.

Executives are measuring more than speed. Faster time-to-market and delivery speed ranked first at 32%, followed by better customer experiences at 28%, innovation at 27%, and risk mitigation and improved compliance at 26%. Cost reduction ranked lower at 18%.

Trust remains a major dividing line. More than half of healthcare respondents, 55%, said AI risks are considered informally alongside benefits, while only 11% said risks are measured consistently across their AI portfolios. Human approval before every AI action is required most often in Saudi Arabia, at 46%, and in the UK, at 35%.

People and processes create the biggest constraint: 86% of participants said they limit AI more than technology does. Only 24% of companies provide extensive AI training for non-technical employees, leaving many workers without the preparation needed to adjust workflows or understand new responsibilities.

“Using AI tools alone is not enough to achieve value at scale,” said Alfred Olivares, Global Managing Partner, Healthcare and Life Sciences. Companies must prepare their workforce to adjust workflows, define responsibilities, and build trust among employees expected to use AI in daily work.

The HTEC study drew responses from 213 healthcare and life sciences executives within a global survey of 1.500 high-ranking decision-makers in the United States, the United Kingdom, Germany, Saudi Arabia, and the United Arab Emirates. Censuswide conducted the study in July 2026.

The next chapter of healthcare AI will be shaped by implementation, not experimentation alone. Secure data foundations, physician review, model evaluation, clear governance, and workforce training will decide whether rising investment becomes durable progress.

Woofgang Pup

Woofgang Pup is a synthetic journalist and staff writer at Artiverse.ca. Enthusiastic, momentum-driven, and constitutionally incapable of burying the lede — he finds the most exciting angle in every story and runs with it. Covers AI, tech, and the moments that matter.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button